3.財務諸表及び主な注記
(1)貸借対照表
| | (単位:千円) |
| 前事業年度 (2024年3月31日) | 当事業年度 (2025年3月31日) |
資産の部 | | |
流動資産 | | |
現金及び預金 | 4,266,344 | 3,885,449 |
受取手形 | 4,371 | 4,371 |
売掛金 | 521,923 | 539,201 |
電子記録債権 | 82,362 | 50,625 |
商品及び製品 | - | 1,928 |
仕掛品 | 55,679 | 17,142 |
原材料及び貯蔵品 | 172,886 | 162,629 |
前払費用 | 32,059 | 30,969 |
その他 | 203,651 | 132,630 |
流動資産合計 | 5,339,279 | 4,824,949 |
固定資産 | | |
有形固定資産 | | |
建物 | 2,016,976 | 2,017,226 |
減価償却累計額 | △1,339,491 | △1,408,924 |
建物(純額) | 677,485 | 608,302 |
構築物 | 20,382 | 20,382 |
減価償却累計額 | △18,904 | △18,974 |
構築物(純額) | 1,477 | 1,408 |
機械及び装置 | 497,224 | 537,305 |
減価償却累計額 | △372,761 | △386,758 |
機械及び装置(純額) | 124,462 | 150,547 |
工具、器具及び備品 | 391,777 | 410,803 |
減価償却累計額 | △330,389 | △348,236 |
工具、器具及び備品(純額) | 61,387 | 62,566 |
土地 | 582,770 | 582,770 |
建設仮勘定 | 63,296 | 14,660 |
有形固定資産合計 | ※ 1,510,880 | ※ 1,420,255 |
無形固定資産 | | |
ソフトウエア | 23,165 | 76,753 |
その他 | 79,362 | 19,997 |
無形固定資産合計 | 102,527 | 96,750 |
投資その他の資産 | | |
投資有価証券 | - | 150,000 |
出資金 | 20 | 20 |
長期前払費用 | 34,172 | 20,107 |
その他 | 1,894 | 906 |
投資その他の資産合計 | 36,086 | 171,034 |
固定資産合計 | 1,649,495 | 1,688,040 |
資産合計 | 6,988,774 | 6,512,990 |
| | (単位:千円) |
| 前事業年度 (2024年3月31日) | 当事業年度 (2025年3月31日) |
負債の部 | | |
流動負債 | | |
買掛金 | 19,573 | 24,890 |
電子記録債務 | 64,014 | 84,391 |
未払金 | 210,469 | 187,195 |
未払費用 | 19,646 | 21,260 |
未払法人税等 | 35,443 | 21,264 |
契約負債 | 82,395 | 39,798 |
預り金 | 16,972 | 10,210 |
賞与引当金 | 161,792 | 127,186 |
役員賞与引当金 | - | 3,397 |
その他 | 263,224 | 117,633 |
流動負債合計 | 873,531 | 637,229 |
固定負債 | | |
退職給付引当金 | - | 4,725 |
役員退職慰労引当金 | 34,900 | 46,000 |
固定負債合計 | 34,900 | 50,725 |
負債合計 | 908,431 | 687,954 |
純資産の部 | | |
株主資本 | | |
資本金 | 4,958,763 | 4,958,763 |
資本剰余金 | | |
資本準備金 | 2,788,763 | 2,788,763 |
資本剰余金合計 | 2,788,763 | 2,788,763 |
利益剰余金 | | |
その他利益剰余金 | | |
繰越利益剰余金 | △1,666,875 | △1,922,179 |
利益剰余金合計 | △1,666,875 | △1,922,179 |
自己株式 | △308 | △311 |
株主資本合計 | 6,080,342 | 5,825,035 |
純資産合計 | 6,080,342 | 5,825,035 |
負債純資産合計 | 6,988,774 | 6,512,990 |
E0235777740株式会社ジャパン・ティッシュエンジニアリングJapan Tissue Engineering Co., Ltd.通期第2号参考様式 [日本基準](非連結)Japan GAAPfalseCTE2024-04-012025-03-31FY2025-03-312023-04-012024-03-312024-03-311falsefalsefalse777402024-04-012025-03-31jppfs_cor:NonConsolidatedMember777402024-03-31jppfs_cor:NonConsolidatedMember777402023-04-012024-03-31jppfs_cor:NonConsolidatedMember777402023-03-31jppfs_cor:NonConsolidatedMember777402024-03-31jppfs_cor:LegalCapitalSurplusMemberjppfs_cor:NonConsolidatedMember777402024-03-31jppfs_cor:NonConsolidatedMemberjppfs_cor:RetainedEarningsBroughtForwardMember777402024-03-31jppfs_cor:NonConsolidatedMemberjppfs_cor:ShareholdersEquityMember777402025-03-31jppfs_cor:NonConsolidatedMemberjppfs_cor:ShareholdersEquityMember777402025-03-31jppfs_cor:NonConsolidatedMemberjppfs_cor:CapitalStockMember777402025-03-31jppfs_cor:LegalCapitalSurplusMemberjppfs_cor:NonConsolidatedMember777402025-03-31jppfs_cor:NonConsolidatedMemberjppfs_cor:RetainedEarningsBroughtForwardMember777402024-04-012025-03-31jppfs_cor:NonConsolidatedMemberjppfs_cor:ShareholdersEquityMember777402024-04-012025-03-31jppfs_cor:NonConsolidatedMemberjppfs_cor:CapitalStockMember777402024-04-012025-03-31jppfs_cor:NonConsolidatedMemberjppfs_cor:LegalCapitalSurplusMember777402024-04-012025-03-31jppfs_cor:NonConsolidatedMemberjppfs_cor:RetainedEarningsBroughtForwardMember777402023-03-31jppfs_cor:NonConsolidatedMemberjppfs_cor:CapitalStockMember777402023-03-31jppfs_cor:NonConsolidatedMemberjppfs_cor:LegalCapitalSurplusMember777402023-03-31jppfs_cor:NonConsolidatedMemberjppfs_cor:RetainedEarningsBroughtForwardMember777402023-03-31jppfs_cor:NonConsolidatedMemberjppfs_cor:ShareholdersEquityMember777402023-04-012024-03-31jppfs_cor:NonConsolidatedMemberjppfs_cor:RetainedEarningsBroughtForwardMember777402023-04-012024-03-31jppfs_cor:CapitalStockMemberjppfs_cor:NonConsolidatedMember777402023-04-012024-03-31jppfs_cor:NonConsolidatedMemberjppfs_cor:LegalCapitalSurplusMember777402023-04-012024-03-31jppfs_cor:NonConsolidatedMemberjppfs_cor:ShareholdersEquityMember777402024-03-31jppfs_cor:NonConsolidatedMemberjppfs_cor:CapitalStockMember777402025-03-31jppfs_cor:TreasuryStockMemberjppfs_cor:NonConsolidatedMember777402024-04-012025-03-31jppfs_cor:TreasuryStockMemberjppfs_cor:NonConsolidatedMember777402024-03-31jppfs_cor:TreasuryStockMemberjppfs_cor:NonConsolidatedMember777402023-04-012024-03-31jppfs_cor:TreasuryStockMemberjppfs_cor:NonConsolidatedMember777402023-03-31jppfs_cor:TreasuryStockMemberjppfs_cor:NonConsolidatedMember777402025-03-31jppfs_cor:NonConsolidatedMember777402025-04-30777402024-04-012025-03-31777402024-04-012025-03-31jppfs_cor:NonConsolidatedMemberjpcrp_cor:ReportableSegmentsMember777402024-03-31jppfs_cor:NonConsolidatedMemberjpcrp_cor:ReportableSegmentsMember777402023-04-012024-03-31jppfs_cor:NonConsolidatedMemberjpcrp_cor:ReportableSegmentsMember777402025-03-31jppfs_cor:NonConsolidatedMemberjpcrp_cor:ReportableSegmentsMember777402024-04-012025-03-31jppfs_cor:NonConsolidatedMembertse-anedjpfr-77740:RegenerativeMedicineBusinessReportableSegmentsMember777402024-04-012025-03-31jppfs_cor:NonConsolidatedMembertse-anedjpfr-77740:CustomDevelopmentAndManufacturingBusinessReportableSegmentsMember777402024-04-012025-03-31jppfs_cor:NonConsolidatedMembertse-anedjpfr-77740:ResearchAndDevelopmentSupportBusinessReportableSegmentsMember777402024-04-012025-03-31jppfs_cor:NonConsolidatedMemberjpcrp_cor:ReconcilingItemsMember777402024-03-31jppfs_cor:NonConsolidatedMembertse-anedjpfr-77740:RegenerativeMedicineBusinessReportableSegmentsMember777402024-03-31jppfs_cor:NonConsolidatedMembertse-anedjpfr-77740:CustomDevelopmentAndManufacturingBusinessReportableSegmentsMember777402024-03-31jppfs_cor:NonConsolidatedMembertse-anedjpfr-77740:ResearchAndDevelopmentSupportBusinessReportableSegmentsMember777402024-03-31jppfs_cor:NonConsolidatedMemberjpcrp_cor:ReconcilingItemsMember777402023-04-012024-03-31jppfs_cor:NonConsolidatedMembertse-anedjpfr-77740:RegenerativeMedicineBusinessReportableSegmentsMember777402023-04-012024-03-31jppfs_cor:NonConsolidatedMembertse-anedjpfr-77740:CustomDevelopmentAndManufacturingBusinessReportableSegmentsMember777402023-04-012024-03-31jppfs_cor:NonConsolidatedMembertse-anedjpfr-77740:ResearchAndDevelopmentSupportBusinessReportableSegmentsMember777402023-04-012024-03-31jppfs_cor:NonConsolidatedMemberjpcrp_cor:ReconcilingItemsMember777402025-03-31jppfs_cor:NonConsolidatedMembertse-anedjpfr-77740:RegenerativeMedicineBusinessReportableSegmentsMember777402025-03-31jppfs_cor:NonConsolidatedMembertse-anedjpfr-77740:CustomDevelopmentAndManufacturingBusinessReportableSegmentsMember777402025-03-31jppfs_cor:NonConsolidatedMembertse-anedjpfr-77740:ResearchAndDevelopmentSupportBusinessReportableSegmentsMember777402025-03-31jppfs_cor:NonConsolidatedMemberjpcrp_cor:ReconcilingItemsMemberxbrli:pureiso4217:JPY